Overview of Duphalac 66.5%

Quick Facts

Property	Description
Active ingredient	Lactulose
Form	Oral Solution (66.5% w/v)
Pharmacological class	Osmotic Laxative / Prebiotic
General purpose	Bowel regularity management
Origin	Synthetic disaccharide

Defining Duphalac 66.5%: A Synthetic Osmotic Laxative

Duphalac 66.5% is a medicinal preparation featuring Lactulose as its active ingredient, which places it within the dual classification of an Osmotic Laxative and a Prebiotic. This preparation is used as a bowel regulator, acting locally to promote natural physiological regularity.

Lactulose is a synthetic disaccharide, meaning it is a chemically produced sugar compound not naturally digested or absorbed by the human body. Its unique chemical structure allows it to reach the colon intact, where its effects are initiated. The primary classification, Osmotic Laxative, is recognized for its ability to increase the water content in the large intestine. Furthermore, its prebiotic property confirms its role in modulating the colonic microflora, distinguishing it from inert osmotic agents.

Composition, Form, and Origin of Lactulose Solution

Duphalac is formulated as an oral solution with a high concentration of 66.5% w/v (weight per volume), where the Lactulose is dissolved in an aqueous vehicle. This specific liquid form facilitates convenient oral administration. The formulation is highly standardized, which is characteristic of this single-component product.

The active substance, Lactulose, is a chemically distinct compound formed from Fructose and Galactose. As a result of its dedicated synthesis process, it is classified as a synthetic compound. The non-systemic nature of the drug’s primary action means that the beneficial effects are concentrated in the gut without significant systemic absorption.

The General Purpose of Duphalac 66.5%

The general purpose of Duphalac is to aid in the maintenance of regular bowel function by improving the consistency of stools. This therapeutic goal is achieved by retaining water in the colon, which softens and increases the bulk of the stool. This localized action provides functional support for easier, less strenuous elimination, establishing its core benefit for managing difficulties associated with infrequent or hard bowel movements.

Regulatory References

NIH/MedlinePlus

What side effects are possible with Duphalac 66.5%?

Possible side effects and safety information

The safety profile of Duphalac (Lactulose solution) is characterized primarily by effects on the gastrointestinal system, which align with its localized action in the gut. Adverse reactions are formally classified by frequency in regulatory documents, with most effects being temporary and often dose-related.

Adverse Reactions Classified by Frequency

Official regulatory sources classify potential effects into the following categories:

Classification	Example Adverse Reaction
Very Common	Diarrhoea
Common	Flatulence, Abdominal pain, Nausea, Vomiting
Uncommon	Electrolyte imbalance (linked to diarrhoea)
Not Known	Hypersensitivity reactions (e.g., rash, pruritus)

These effects fall under System-Organ Classes including Gastrointestinal Disorders, Metabolism and Nutrition Disorders, and Immune System Disorders.

Safety Considerations and Restrictions

Certain safety patterns and limitations are documented in official labeling:

Dose-Related Patterns: Diarrhoea and the potential for subsequent fluid and electrolyte disturbances are explicitly noted as consequences of high or prolonged doses. Flatulence is common at the initiation of treatment and typically subsides within a few days.
Serious Adverse Potential: The primary risk associated with excessive or unadjusted dosing is the potential for severe electrolyte disturbances and resulting dehydration.
Contraindications: Use of Duphalac is formally restricted in individuals with conditions such as galactosaemia, gastrointestinal obstruction, or the presence of acute inflammatory bowel diseases like Crohn’s disease or ulcerative colitis. Specific caution is also documented for diabetic patients due to the solution's minor content of related sugars.

The regulatory documentation emphasizes that the risk of serious adverse reactions is directly linked to the dose administered and duration of treatment, establishing a strict framework for understanding its official safety profile.

Overdose and Emergency Response

Overdosage with Lactulose solution is officially documented to manifest primarily through severe, persistent diarrhea and pronounced abdominal cramps or pain. Other associated clinical presentations may include nausea and vomiting.

The most critical consequence of exceeding the documented dose is extensive fluid loss, which can rapidly lead to significant electrolyte disturbances. This physiological imbalance creates the risk of developing severe conditions such as hypokalemia (low blood potassium) and hypernatremia (high blood sodium). Regulatory sources note that elderly or acutely ill patients may be at an increased risk for these severe metabolic effects due to the risk of accelerated fluid depletion.

In any confirmed or suspected case of overdosage, regulatory labeling mandates that individuals contact a healthcare practitioner, hospital emergency department, or a Poison Control Center immediately. The first action required to manage symptoms is the cessation of treatment or an immediate dose reduction. Treatment procedures are described as strictly symptomatic and supportive, focusing on fluid and electrolyte replacement and the correction of electrolyte disturbances, as it is officially stated that no specific antidote is known for this compound.

Therapeutic Uses of Duphalac 66.5%

What Duphalac 66.5% Treats: Main Uses and Benefits

Duphalac 66.5% (Lactulose solution) is used in situations involving certain distressing symptoms. It is commonly used across domains where additional symptomatic support is needed, aiming to contribute to easing the overall symptom load and support patients during episodes of heightened discomfort. The medicine is primarily applied in addressing symptom clusters related to chronic constipation and hepatic encephalopathy (HE). This supportive use is relevant in contexts marked by increased discomfort or tension.

Symptomatic Relief for Chronic Constipation

This formulation is used to help with symptomatic relief in conditions involving episodic or fluctuating manifestations of chronic constipation. It helps address symptom clusters that create noticeable physiological strain, such as difficulty passing stools and significant discomfort. The therapeutic benefit contributes to easing the overall symptom load and supports general well-being during symptomatic phases.

“It supports the patient during difficult episodes by easing distress.”

Supportive Management in Hepatic Encephalopathy

Duphalac is also applied across domains where additional symptomatic support is needed in conditions where functional stability becomes affected, such as those used in situations involving certain distressing symptoms (e.g., HE). This is relevant when supportive symptom management is appropriate. In this domain, it helps address groups of symptoms that interfere with daily functioning, and assists with maintaining functional stability and supporting patients during difficult episodes.

Quick Fact: Relevant for Symptoms that Interfere with Daily Functioning

Regulatory References

NIH DailyMed overview

Eligibility and Restrictions for Use

Duphalac 66.5% (Lactulose solution) is subject to strict eligibility rules outlined in official regulatory documents. Use is absolutely contraindicated in patients diagnosed with Galactosaemia or those who require a low-galactose diet, due to residual sugars from the manufacturing process. The medicine must also not be used if there is a known hypersensitivity to the active substance or its excipients, or if the patient presents with a gastrointestinal obstruction, perforation, or risk of perforation. Individuals with rare hereditary intolerances, such as total lactase deficiency or glucose-galactose malabsorption, are also officially excluded from use.

Adults and adolescents are permitted to use Duphalac for its labeled purposes. Eligibility for other populations is specified as follows:

Eligibility Group	Regulatory Status	Constraint Context
Pregnant/Breastfeeding	Permitted	No effects are anticipated due to negligible systemic absorption.
Diabetic Patients	Use with Caution	High doses for Hepatic Encephalopathy (HE) may need to be considered.
Children (for HE)	Use Not Established	Safety and efficacy for HE treatment in patients under 18 years are not established.
Children (for Constipation)	Permitted	Use is allowed but recommended under medical supervision.

No special recommendations exist for use in elderly patients or those with renal or hepatic impairment, consistent with the drug's negligible systemic exposure.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation identifies interactions with other medicinal products primarily related to either functional antagonism within the colon or additive systemic risk concerning electrolyte balance. As the active ingredient, Lactulose, is minimally absorbed, its interaction profile focuses on local effects and resulting physiological changes.

Documented Interaction Patterns

Interacting Product Category	Official Interaction Statement
Nonabsorbable Antacids	Co-administration may inhibit the desired lactulose-induced drop in colonic pH, which may reduce the medicine's expected local efficacy.
Oral Anti-infective Agents	Certain agents may interfere with the essential bacterial degradation of lactulose in the colon, potentially leading to an inadequate therapeutic response.
Diuretics and Corticosteroids	Chronic use of Lactulose may cause hypokalemia; concurrent use of these potassium-lowering agents may increase the risk of low serum potassium due to an additive effect.
Other Laxatives	Concurrent use is cautioned, particularly during treatment for Hepatic Encephalopathy, as loose stools may complicate the proper assessment of the required dose.

Population and Timing Notes

Timing-Based Rules: The official regulatory labeling does not specify any mandatory separation windows for administration, such as requiring doses to be separated by a specific number of hours.
Long-term Use: For patients on long-term treatment (over six months), official guidelines recommend monitoring for electrolyte imbalance, which is a critical consideration when these patients are also taking interacting agents. The regulatory profile establishes clear constraints against substances that counteract the intended acidic colonic environment or contribute to the risk of hypokalemia.

Mechanism of Action

Microbiota-Initiated Osmotic Modulation

The mechanism is initiated by colonic saccharolytic bacteria which ferment the unabsorbed lactulose into short-chain fatty acids (SCFAs). The presence of these metabolites and residual lactulose creates a substantial osmotic gradient, drawing water into the colon. This influx of water increases the hydration of the fecal mass and increases its volume, which mechanically stimulates colonic peristalsis and accelerates intestinal transit.

pH-Driven Ammonia Trapping Mechanism

The production of SCFAs significantly lowers the pH within the colon. This acidic environment promotes the pH partitioning (ion trapping) of freely diffusible ammonia ( NH3) by converting it into non-absorbable ammonium ( NH4^+). This chemical process results in the excretion of ammonia that has diffused from the systemic circulation, as the trapped ion is excreted from the body via the osmotic cathartic action.

Dosage and Administration Information

How to Use Duphalac 66.5% - Official Administration Guidelines

Duphalac 66.5% (Lactulose solution) is administered according to specific protocols that define the route, dosage, and frequency based on the condition being addressed.

Administration Routes and Frequency

The approved routes for this solution are primarily oral administration; however, the rectal route (as a retention enema) is designated for the initial management of specific conditions, such as portal-systemic encephalopathy. The frequency of use is tied directly to the condition and therapeutic phase.

Condition	Starting Adult Dosing Regimen	Frequency and Adjustment
Chronic Constipation	15 mL to 45 mL daily (10 g to 30 g lactulose).	May be taken as a single daily dose or in two divided doses.
Hepatic Encephalopathy (HE)	30 mL to 45 mL (20 g to 30 g) three to four times daily.	Dose is titrated to produce two to three soft stools daily.

Preparation and Procedural Rules

When administered orally, the solution may be taken undiluted or mixed with a glass of water, milk, or fruit juice to improve palatability. If taking a single daily dose, it is recommended to maintain a consistent schedule, such as administration with breakfast. The solution typically requires 24 to 48 hours before the desired bowel movement occurs.

Patients should ensure sufficient fluid intake (approximately 1.5 to 2 litres daily) during the period of administration. Pediatric use is not standardised and requires dose determination and supervision by a healthcare professional. In the event of a missed dose, the forgotten dose should generally be skipped if it is almost time for the next scheduled dose and the regular timing resumed, without taking two doses simultaneously.

These instructions define the standardized route, dosage boundaries, and required titration principles necessary for the consistent and proper use of the medicine.

Recent Clinical Evidence

Research evidence / Overview of Studies for Duphalac 66.5%

This section provides a summary of the clinical research conducted on the active ingredient, lactulose, focusing on the types of studies that exist, the outcomes they measured, and the overall quality of the resulting evidence, as noted by regulatory bodies and peer-reviewed literature. Research provides context but not individual predictions; study results reflect the specific conditions under which they were conducted.

Evidence for Use in Chronic Constipation

The evidence base for the use of this solution that was studied for chronic constipation, a condition characterized by fluctuating or episodic manifestations, consists primarily of short-term Randomized Controlled Trials (RCTs) and subsequent systematic reviews. These studies were used in research exploring how symptoms change over time and often compared the solution against a placebo or another substance used in the trials.

What researchers studied: Research examined outcomes related to physical discomfort and physiological strain, such as the frequency of spontaneous bowel movements (SBMs) per week, and studies monitored changes in stool consistency using standardized instruments. Findings describe patterns observed in the studies over these limited observation periods, focusing on measured changes in the frequency of SBMs. Reports consistently documented patterns related to gastrointestinal-related events (such as flatulence and abdominal distension) across the observed populations.

Evidence for Supportive Management of Hepatic Encephalopathy (HE)

Research on the supportive use of this solution for Hepatic Encephalopathy (HE), a condition marked by functional limitations and periods of heightened symptom activity, includes RCTs, older non-blinded studies, and comprehensive meta-analyses. This evidence was derived from settings with varying symptom burdens.

What researchers studied: Studies explored outcomes related to systemic or functional imbalance, specifically the outcome status of overt HE symptoms (tracked using specific grading scales) and rates of episode occurrence in adult patients with liver cirrhosis. Findings indicate that the solution was studied in relation to rates of episode occurrence over defined time intervals. Regulatory reviews often cite that the evidence quality varies across studies, noting the presence of potential bias factors in the methodologies of several older trials that contributed to the initial evidence base.

What Remains Uncertain in the Research

The majority of primary RCTs for both indications are relevant in trials assessing short-term or episodic symptom patterns, meaning follow-up durations were limited. Limited comparative data exists for some newer treatment options, and long-term effects are not fully established for either indication. Data for certain specific patient groups or complex comorbidities remain insufficient. Studies help show what has been observed so far, but the evidence describes group patterns, not personal outcomes.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Duphalac 66.5% (FAQ)

Q: Why does Duphalac take longer to work compared to some other laxatives?

A: The time required for Duphalac to work is determined by its mechanism of action. The medicine must be broken down by colonic bacteria first to create the osmotic effect that draws water into the colon. This process means that the desired bowel movement typically requires 24 to 48 hours to occur after administration.

Q: Is it normal to experience a lot of gas and bloating when first starting Duphalac?

A: Yes, official product information notes that flatulence (gas) and abdominal pain are common side effects. Flatulence is often reported at the initiation of treatment. This gas production is part of the drug's mechanism of action, which involves fermentation by gut bacteria.

Q: Do the side effects like flatulence usually lessen over time after starting the medication?

A: Regulatory documents indicate that the side effect of flatulence is often temporary. It is expected to subside within a few days of continuous use as the body adjusts to the treatment.

Q: Can Duphalac be taken long-term for chronic constipation, or is it only for short-term use?

A: Duphalac is indicated for chronic constipation. However, for patients receiving long-term treatment (over six months), official guidelines recommend regular monitoring for electrolyte imbalance. This recommendation is in place to allow monitoring for the body's mineral balance during prolonged use.

Q: Are there any specific foods or drinks that should be avoided when taking Duphalac?

A: Official warnings focus on the medicine's minor content of related sugars. Due to this, Duphalac should not be used in patients who require a low-galactose diet. Regulatory documents primarily focus on the exclusion for patients who require a low-galactose diet.

Q: Does Duphalac affect the absorption of other oral medications I take?

A: The active ingredient, Lactulose, is minimally absorbed into the bloodstream. Therefore, its interaction profile focuses mainly on local effects in the colon, such as interference from antacids or antibiotics that might reduce its efficacy. Systemic exposure is negligible.

Q: Can Duphalac impact the results of a colonoscopy or other intestinal tests?

A: The preparation for procedures like a colonoscopy typically requires specific bowel cleansing medicines as determined by a healthcare professional. Duphalac is generally not used alone for this purpose, and specific instructions must be obtained prior to the procedure.

Q: What is the usual time frame for Duphalac to start working after the first dose?

A: The desired therapeutic effect—the bowel movement—typically requires 24 to 48 hours to occur after administration. This expected delay is due to the time needed for the medicine to reach the colon and be activated.

Q: What is the role of the bacteria in the gut in making Duphalac effective?

A: The colonic bacteria are essential for Duphalac to work. They ferment (break down) the lactulose into specific acids that create the osmotic effect to draw water into the stool, making it softer and easier to pass.

Q: Is Duphalac effective for constipation caused by opioid pain medications?

A: Official guidance for essential medicines includes the use of Lactulose for the prevention of constipation in patients taking opioid analgesics. Its use in this context is based on its osmotic action, which helps maintain stool hydration.

Q: Does Duphalac come in any other form besides a syrup or liquid solution?

A: The active ingredient, Lactulose, is most commonly formulated as an oral solution (syrup). However, official sources note that it can also be available in the form of a powder for oral solution (packet) in various markets.

Q: Is there any evidence Duphalac affects the gut microbiome?

A: Yes, Duphalac is classified in pharmacological studies as a Prebiotic. This designation reflects its known role in modulating the colonic microflora (the gut microbiome) by promoting the growth and activity of beneficial bacteria in the colon.

Q: How quickly should I see a reduction in gas and bloating after starting Duphalac?

A: Official data indicates that the common side effects of flatulence and bloating typically improve over time. These effects usually subside within a few days of continuous therapy.

Q: Does taking Duphalac at the same time every day improve its effectiveness?

A: Regulatory guidance suggests a consistent daily schedule for single doses, such as taking it with breakfast, which can support adherence to the treatment plan. However, there is no claim that this specifically improves the medicine's physical action.

Q: What should I do if the Duphalac solution changes color and gets darker?

A: A normal slight darkening of color is expected during storage and does not affect the medicine's action. However, if the solution becomes extremely dark, cloudy, or thickens (which may occur if improperly stored), contacting a healthcare professional or pharmacist is recommended before use.

Q: Can Duphalac be used to treat fecal impaction?

A: While the primary indications are Chronic Constipation and Hepatic Encephalopathy, Lactulose has been documented in certain medical guidelines as effective for treating impacted stool in specific clinical settings. Its action helps by hydrating and softening the impacted mass.

Q: Can Duphalac be taken with or without food?

A: According to official administration instructions, Duphalac can be taken with or without food. For ease of administration, the solution can be taken undiluted or mixed with a liquid like water or juice.

Q: What is the difference between Duphalac and the generic lactulose solution?

A: Duphalac is a branded product containing the active ingredient lactulose. Generic lactulose solutions contain the same active ingredient in the same concentration. Both are considered chemically equivalent.

Q: Is Duphalac safe for children, and what are the general age guidelines?

A: Official guidance indicates that most adults and young people aged 14 years and over can take it. For babies and children under 14, the medicine is only permitted for use in this age group when recommended by a healthcare professional for constipation.

Q: Are there any signs that a Duphalac dosage might be too high?

A: The clearest clinical sign of an excessive dose is diarrhea. Persistent or severe diarrhea may lead to fluid loss and electrolyte disturbances (such as low potassium). If diarrhea develops, consult a healthcare professional regarding the dosage.

How should Duphalac 66.5% be stored and disposed of?

Storage and Disposal of Duphalac 66.5% Oral Solution

Storage Requirements

Duphalac oral solution must be stored in a cool place where the temperature stays below 25°C (77°F). It is mandatory to keep the medicine out of the sight and reach of children.

Condition	Requirement (Official Labeling)
Temperature	Store below 25°C; avoid temperatures above 30°C.
Protection	Protect from prolonged exposure to direct light.
Prohibitions	Do not store in the refrigerator or the freezer.

Freezing may cause the solution to thicken into a semisolid, and prolonged exposure to high heat or light may cause the solution to become very dark and cloudy, indicating it should not be used. A normal slight darkening of color, however, does not affect the medicine's action.

Disposal Instructions

Duphalac must not be disposed of via household waste or wastewater (e.g., flushing it down the toilet). Any unused or expired solution must be returned to the pharmacist for proper disposal.

Duphalac 66.5%